Precision oncology program for advanced cancer patients
Research Collaboration for a Precision Oncology Program (POP)
This study is testing a new way to personalize cancer treatment for people with advanced cancer by looking closely at their tumors to see which therapies might work best for them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Zurich Academic / other |
| Locations | 1 site (Zurich) |
| Trial ID | NCT06680726 on ClinicalTrials.gov |
What this trial studies
The Precision Oncology Program (POP) is an observational collaboration aimed at generating insights into the individual tumor biology of patients with advanced malignancies. By utilizing innovative biotechnologies and comparing patient profiles against specific databases, the program seeks to inform clinical decision-making regarding potential treatment benefits. The study includes routine genetic testing and advanced imaging mass cytometry to capture tumor heterogeneity and predict therapy responses. This approach aims to integrate precision oncology into clinical practice effectively.
Who should consider this trial
Good fit: Ideal candidates include patients diagnosed with solid tumors such as adenocarcinoma, squamous cell carcinoma, neuroendocrine carcinoma, or sarcoma, with an ECOG performance status of 0-2.
Not a fit: Patients with blood cancers will not benefit from this study.
Why it matters
Potential benefit: If successful, this program could enhance personalized treatment strategies for patients with advanced cancers, potentially improving outcomes.
How similar studies have performed: Other studies have shown success with similar precision oncology approaches, indicating a promising avenue for advancing cancer treatment.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Signed informed consent * In the case of deceased persons: signed general consent * All patients with the diagnosis of a solid tumour including adenocarcinoma, squamous cell carcinoma, neuroendocrine carcinoma, sarcoma, etc * ECOG-performance status 0-2, if applicable * Willing and able to understand all project related procedures, including transfer of coded (i.e. pseudonymised) or anonymized clinical data to external partners (e.g. Roche), if applicable Exclusion Criteria: * Patients with the diagnosis of blood cancer.
Where this trial is running
Zurich
- University Hospital Zürich (Universitätsspital Zürich) — Zurich, Switzerland (Recruiting)
Study contacts
- Study coordinator: Andreas Wicki, Professor
- Email: andreas.wicki@usz.ch
- Phone: +41 44 255 38 99
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.